CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

CDK4 and CDK6 kinases: From basic science to cancer therapy

(2022) Anne Fassl et al.   SCIENCE

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

(2022) Eugene Y Chiang et al.   Journal for ImmunoTherapy of Cancer

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy

(2022) Hirohito Yamaguchi et al.   Clinical and Translational Medicine

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα

(2022) Dong Guo et al.   Cell Metabolism

Progression to Metastasis of Solid Cancer

(2021) Eldad Zacksenhaus et al.   Cancers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

(2021) D. Miles et al.   ANNALS OF ONCOLOGY

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

(2021) Fabin Dang et al.   Nature Communications

254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity

(2021) Anas Atieh et al.   Journal for ImmunoTherapy of Cancer

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

(2020) Preeti Narayan et al.   CLINICAL CANCER RESEARCH

Regulation of PD-L1 Expression by NF-κB in Cancer

(2020) Fabrizio Antonangeli et al.   Frontiers in Immunology

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

(2019) Bo Gong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Two Distinct E2F Transcriptional Modules Drive Cell Cycles and Differentiation

(2019) Maria C. Cuitiño et al.   Cell Reports

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

(2019) Jiayi Yu et al.   CLINICAL CANCER RESEARCH

Molecular stratification within triple-negative breast cancer subtypes

(2019) Dong-Yu Wang et al.   Scientific Reports

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

(2018) Jung-Mao Hsu et al.   Nature Communications

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

(2018) Jeff C. Liu et al.   Cell Reports

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

(2018) Kathleen M. Mahoney et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

(2018) Livnat Jerby-Arnon et al.   CELL

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Targeting PVR (CD155) and its receptors in anti-tumor therapy

(2018) Paola Kučan Brlić et al.   Cellular & Molecular Immunology

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

(2018) Xin Jin et al.   MOLECULAR CELL

Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors

(2018) Andrew Dhawan et al.   Nature Communications

Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene

(2018) Xueqian Gong et al.   Cancer Discovery

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Integrative clinical genomics of metastatic cancer

(2017) Dan R. Robinson et al.   NATURE

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

The RB–IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity

(2017) S Kitajima et al.   ONCOGENE

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation

(2016) Robert A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

NF- B Gene Signature Predicts Prostate Cancer Progression

(2014) R. Jin et al.   CANCER RESEARCH

Poliovirus Receptor (CD155) Regulates a Step in Transendothelial Migration between PECAM and CD99

(2013) David P. Sullivan et al.   AMERICAN JOURNAL OF PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

A pathway-based classification of human breast cancer

(2010) M. L. Gatza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential

(2009) E. R. Andrechek et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation

(2008) Yoshimi Takai et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY